ipilimumab [Ipilimumab]

tematický
253
Termíny

Yervoy

 

Anti-CTLA-4 MAb Ipilimumab
MDX 010
MDX-010
MDX-CTLA-4
MDX010
Yervoy

Perzistentní odkaz   https://www.medvik.cz/link/D000074324
Definice

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

DUI
D000074324 MeSH Prohlížeč
CUI
M000626138
Historická pozn.
2018(2012)
Veřejná pozn.
2018; IPILIMUMAB was indexed under ANTIBODIES, MONOCLONAL, 2012-2017

D Chemikálie a léčiva
D12.776 proteiny 2 577
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 489
D12.776.124.486.485.114 protilátky 1 815
D12.776.124.486.485.114.224 monoklonální protilátky 4 629
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 790
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 347
D12.776.124.486.485.114.224.060.313 alemtuzumab 123
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 445
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 40
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 185
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 150
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 253
D12.776.124.486.485.114.224.060.813 natalizumab 156
D12.776.124.486.485.114.224.060.829 nivolumab 432
D12.776.124.486.485.114.224.060.844 omalizumab 112
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 57
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 61
D12.776.124.486.485.114.224.060.875 trastuzumab 269
D12.776.124.486.485.114.224.060.937 ustekinumab 121
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 489
D12.776.124.790.651.114 protilátky 1 815
D12.776.124.790.651.114.224 monoklonální protilátky 4 629
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 790
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 347
D12.776.124.790.651.114.224.060.375 alemtuzumab 123
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 445
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 40
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 185
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 150
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 253
D12.776.124.790.651.114.224.060.813 natalizumab 156
D12.776.124.790.651.114.224.060.829 nivolumab 432
D12.776.124.790.651.114.224.060.844 omalizumab 112
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 57
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 61
D12.776.124.790.651.114.224.060.875 trastuzumab 269
D12.776.124.790.651.114.224.060.937 ustekinumab 121
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 489
D12.776.377.715.548.114 protilátky 1 815
D12.776.377.715.548.114.224 monoklonální protilátky 4 629
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 790
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 347
D12.776.377.715.548.114.224.200.375 alemtuzumab 123
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 445
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 40
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 185
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 150
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 253
D12.776.377.715.548.114.224.200.813 natalizumab 156
D12.776.377.715.548.114.224.200.829 nivolumab 432
D12.776.377.715.548.114.224.200.844 omalizumab 112
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 57
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 61
D12.776.377.715.548.114.224.200.875 trastuzumab 269
D12.776.377.715.548.114.224.200.937 ustekinumab 121